Cistatina C como marcador predictivo de preeclampsia
DOI:
https://doi.org/10.62305/biosana.v6i4.1176Palabras clave:
preeclampsia; Cistatina C; biomarcadores; embarazo; predicciónResumen
La preeclampsia se presenta a partir de las 20 semanas de gestación y afecta entre el 3% y 10% de todos los embarazos, se manifiesta con hipertensión, proteinuria y edemas principalmente bimaleolares. Se asocia con varios factores predisponentes como la obesidad, sobrepeso, DM1 y DM2, hipertensión arterial, trastornos autoinmunes, enfermedad renal, entre otros. Se usan diversos biomarcadores para su diagnóstico, sin embargo, se consideran como determinantes de gravedad, mas no del desarrollo de la Preeclampsia. Por otro lado, la Cistatina C ha sido presentada como un importante biomarcador predictivo de Preeclampsia. Objetivo: Evaluar el uso de la Cistatina C como marcador predictivo de preeclampsia. Metodología: Se realiza una investigación de tipo observacional, descriptivo y corte transversal incluyendo 30 pacientes de 18 a 38 años cursando el primer y segundo trimestre de embarazo, que presenten factores de riesgo relacionados, determinado por medio de una encuesta. Se realizan análisis de orina y suero, cuantificación de Cistatina C por ensayos inmunoturbidimétricos y los resultados reflejan un aumento progresivo en contraste con el desarrollo de la gestación en un 90% de las pacientes. Se concluye que la Cistatina C puede ser considerada un marcador predictivo de preeclampsia en contraste con otros biomarcadores asociados.
Descargas
Citas
Craici, I. M., Wagner, S. J., Weissgerber, T. L., Grande, J. P., & Garovic, V. D. (2014). Advances in the pathophysiology of pre-eclampsia and related podocyte injury. Kidney International, 86(2), 275-285. https://doi.org/10.1038/ki.2014.17
Moreira Flores, M. M., & Montes Vélez, R. S. (2022, marzo). Incidencia y severidad de la preeclampsia en el Ecuador. 8(1), 876-884. https://doi.org/http://dx.doi.org/10.23857/dc.v8i41.2528
Álvarez-Fernández, I., Prieto, B., & Álvarez, F. V. (2016). Preeclampsia. Revista del Laboratorio Clínico, 9(2), 81-89. https://doi.org/10.1016/j.labcli.2016.04.002
Poon, L. C., Shennan, A., Hyett, J. A., Kapur, A., Hadar, E., Divakar, H., McAuliffe, F., Da Silva Costa, F., Von Dadelszen, P., McIntyre, H. D., Kihara, A. B., Di Renzo, G. C., Romero, R., D’Alton, M., Berghella, V., Nicolaides, K. H., & Hod, M. (2019). The International Federation of Gynecology and Obstetrics (FIGO) initiative on pre‐eclampsia: A pragmatic guide for first‐trimester screening and prevention. International Journal of Gynecology & Obstetrics, 145(S1), 1-33. https://doi.org/10.1002/ijgo.12802
Lisonkova, S., & Joseph, K. S. (2013). Incidence of preeclampsia: Risk factors and outcomes associated with early- versus late-onset disease. American Journal of Obstetrics and Gynecology, 209(6), 544.e1-544.e12. https://doi.org/10.1016/j.ajog.2013.08.019
Santa Cruz Pavlovich, F. J., Salmeron Salcedo, C. A., Ponce Rivera, M. S., & Luna Flores, A. (2023). PREECLAMPSIA: REVISIÓN. 5(1). https://doi.org/https://doi.org/10.1016/j.ajog.2013.08.019
Sánchez-Argudo, K. P., Ninasunta-Quisatasig, K. E., & Tufiño-Macas, J. A. (2025). Factores de riesgo en la preeclampsia [Risk factors in preeclampsia]. Sanitas. Revista arbitrada de ciencias de la salud, 4(UNIANDES2), 96-107. https://doi.org/10.62574/c0bnsh52
Franceschini, N., Qiu, C., Barrow, D. A., & Williams, M. A. (2008). Cystatin C and Preeclampsia: A Case Control Study. Renal Failure, 30(1), 89-95. https://doi.org/10.1080/08860220701742229
Cornelis, T., Odutayo, A., Keunen, J., & Hladunewich, M. (2011). The Kidney in Normal Pregnancy and Preeclampsia. Seminars in Nephrology, 31(1), 4-14. https://doi.org/10.1016/j.semnephrol.2010.10.002
Moghaddas Sani, H., Zununi Vahed, S., & Ardalan, M. (2019). Preeclampsia: A close look at renal dysfunction. Biomedicine & Pharmacotherapy, 109, 408-416. https://doi.org/10.1016/j.biopha.2018.10.082
Kristensen, K., Wide‐Swensson, D., Schmidt, C., Blirup‐Jensen, S., Lindström, V., Strevens, H., & Grubb, A. (2007). Cystatin C, β‐2‐microglobulin and β‐trace protein in pre‐eclampsia. Acta Obstetricia et Gynecologica Scandinavica, 86(8), 921-926. https://doi.org/10.1080/00016340701318133
Yang, X., Wang, H., Wang, Z., & Dong, M. (2006). Alteration and significance of serum cardiac troponin I and cystatin C in preeclampsia. Clinica Chimica Acta, 374(1-2), 168-169. https://doi.org/10.1016/j.cca.2006.07.006
Stillman, I. E., & Karumanchi, S. A. (2007). The Glomerular Injury of Preeclampsia. Journal of the American Society of Nephrology, 18(8), 2281-2284. https://doi.org/10.1681/ASN.2007020255
Park, Y. S. (2020). Serum sFlt-1, cystatin C and cathepsin B are potential severity markers in preeclampsia: A pilot study. Archives of Gynecology and Obstetrics.
Inker, L. A., Schmid, C. H., Tighiouart, H., Eckfeldt, J. H., Feldman, H. I., Greene, T., Kusek, J. W., Manzi, J., Van Lente, F., Zhang, Y. L., Coresh, J., & Levey, A. S. (2012). Estimating Glomerular Filtration Rate from Serum Creatinine and Cystatin C. New England Journal of Medicine, 367(1), 20-29. https://doi.org/10.1056/NEJMoa1114248
Visinescu, A.-M., Rusu, E., Cosoreanu, A., & Radulian, G. (2024). CYSTATIN C—A Monitoring Perspective of Chronic Kidney Disease in Patients with Diabetes. International Journal of Molecular Sciences, 25(15), 8135. https://doi.org/10.3390/ijms25158135
Côté, A.-M., Brown, M. A., Lam, E., von Dadelszen, P., Firoz, T., Liston, R. M., & Magee, L. A. (2008). Diagnostic accuracy of urinary spot protein:creatinine ratio for proteinuria in hypertensive pregnant women: Systematic review. BMJ : British Medical Journal, 336(7651), 1003-1006. https://doi.org/10.1136/bmj.39532.543947.BE
Geneen, L. J., Webster, K. E., Reeves, T., Eadon, H., Maresh, M., Fishburn, S., & Chappell, L. C. (2021). Protein-creatinine ratio and albumin-creatinine ratio for the diagnosis of significant proteinuria in pregnant women with hypertension: Systematic review and meta-analysis of diagnostic test accuracy. Pregnancy Hypertension, 25, 196-203. https://doi.org/10.1016/j.preghy.2021.06.013
Thilaganathan, B., Ralph, E., Papageorghiou, A. T., Melchiorre, K., & Sheldon, J. (2009). Raised Maternal Serum Cystatin C: An Early Pregnancy Marker for Preeclampsia. Reproductive Sciences, 16(8), 788-793. https://doi.org/10.1177/1933719109336618
Spencer, S., Desborough, R., & Bhandari, S. (2023). Should Cystatin C eGFR Become Routine Clinical Practice? Biomolecules, 13(7), 1075. https://doi.org/10.3390/biom13071075
Schmitz, E. M., Langelaan, M. L., De Groot, M. J., Ermens, T. A., & Joosen, A. M. (2022). Trimester-specific reference intervals for cystatin C and neutrophil gelatinase-associated lipocalin during pregnancy. Annals of Clinical Biochemistry: International Journal of Laboratory Medicine, 59(3), 199-204. https://doi.org/10.1177/00045632221076354
Anna, O., Anna, T., & Ewa, G. (2015). Cystatin C. En Advances in Clinical Chemistry (Vol. 68, pp. 57-69). Elsevier. https://doi.org/10.1016/bs.acc.2014.11.007
Wattanavaekin, K., Kitporntheranunt, M., & Kreepala, C. (2018). Cystatin C as a novel predictor of preterm labor in severe preeclampsia. Kidney Research and Clinical Practice, 37(4), 338-346. https://doi.org/10.23876/j.krcp.18.0080
Mussap, M., & Plebani, M. (2004). Biochemistry and Clinical Role of Human Cystatin C. Critical Reviews in Clinical Laboratory Sciences, 41(5-6), 467-550. https://doi.org/10.1080/10408360490504934
Liu, N., Guo, Y.-N., Gong, L.-K., & Wang, B.-S. (2021). Advances in biomarker development and potential application for preeclampsia based on pathogenesis. European Journal of Obstetrics & Gynecology and Reproductive Biology: X, 9, 100119. https://doi.org/10.1016/j.eurox.2020.100119
Alshannag, F., Zaki, R. M. M., Hemida, E., ElBakry, M. M. M., & Noureldeen, A. F. H. (2023). Endostatin and Cystatin C as Potential Biomarkers for Early Prediction of Preeclampsia. ACS Omega, 8(45), 42776-42786. https://doi.org/10.1021/acsomega.3c05586
Kolialexi, A., Gourgiotis, D., Daskalakis, G., Marmarinos, A., Lykoudi, A., Mavreli, D., Mavrou, A., & Papantoniou, N. (2015). Validation of Serum Biomarkers Derived from Proteomic Analysis for the Early Screening of Preeclampsia. Disease Markers, 2015, 1-7. https://doi.org/10.1155/2015/121848
Risch, M., Purde, M.-T., Baumann, M., Mohaupt, M., Mosimann, B., Renz, H., Raio, L., Surbek, D., & Risch, L. (2017). High first-trimester maternal blood cystatin C levels despite normal serum creatinine predict pre-eclampsia in singleton pregnancies. Scandinavian Journal of Clinical and Laboratory Investigation, 77(8), 634-643. https://doi.org/10.1080/00365513.2017.1393692
Saleh, S., Antoniou, A. V., Harrington, K., & Aquilina, J. (2010). Second Trimester Maternal Serum Cystatin C Levels in Preeclamptic and Normotensive Pregnancies: A Small Case-Control Study. Hypertension in Pregnancy, 29(1), 112-119. https://doi.org/10.3109/10641950902968627
Pooja Prakash, P., Mahesh, E., Krishnamoorthy, Sujani, B. K., Prachi, & Gurudev, K. C. (2025). First trimester serum Cystatin C level is a predictor of Preeclampsia: A prospective study [Correlation between Shrunken pore syndrome and Preeclampsia] | medRxiv. medRvix The printer server for health science, (1). https://doi.org/https://doi.org/10.64898/2025.12.06.25341768
Thilaganathan, B., Wormald, B., Zanardini, C., Sheldon, J., Ralph, E., & Papageorghiou, A. T. (2010). Early-Pregnancy Multiple Serum Markers and Second-Trimester Uterine Artery Doppler in Predicting Preeclampsia. Obstetrics & Gynecology, 115(6), 1233-1238. https://doi.org/10.1097/AOG.0b013e3181dd5137
Publicado
Cómo citar
Número
Sección
Licencia
Derechos de autor 2026 Revista Científica de Salud BIOSANA
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-CompartirIgual 4.0.
